Denied CGM Appeals: What Reviewers Decided

Continuous glucose monitors and their supply allowances, dispensed for diabetes management and reviewed against criteria covering insulin regimen, testing frequency and hypoglycaemia history.

What the independent reviewers decided

90%

overturned by the independent reviewer

of 30 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny continuous glucose monitor

The policy limits coverage to intensive insulin regimens and the record does not establish one.
The required fingerstick testing frequency is not documented.
A documented hypoglycaemia history the criteria rely on is missing.
The device is classed under a pharmacy benefit the claim did not use.

What actually carried the cases that won

Guideline support led at 52%, with severity and chronicity level at 30% each, and FDA labelling appeared as an authority in 44% of the reversals — an unusually high share that reflects how tightly these devices are labelled for defined populations. The reversals paired a published recommendation with the specific facts the criteria ask for: the regimen, the testing frequency and any hypoglycaemia event, with dates. This is a small sample and the rate should be read as a direction.

What the record showed	Share of overturned decisions
A published guideline supported the request	52%
The severity or urgency was documented	30%
The condition was documented as chronic or long-standing	30%
The diagnosis was confirmed	22%
The functional impact on the patient was documented	11%
Conservative treatment was documented as failed	7%
Prior treatment was documented	7%
Objective findings were documented	4%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Peer-reviewed literature — in 48% of the overturned decisions
FDA labeling — in 44% of the overturned decisions
Clinical guidelines — in 11% of the overturned decisions
Specialty-society criteria — in 4% of the overturned decisions

continuous glucose monitor denials — frequently asked

Is a denied CGM worth appealing?

These denials almost never survived — 27 reversals out of 30 California determinations. Thirty decisions is a small base, so treat that as a strong direction rather than a precise figure.

What does the record need?

The criteria's own facts. The insulin regimen, the documented testing frequency, and any hypoglycaemia event with its date. Guideline support was in 52% of the reversals and FDA labelling in 44%, so pairing the recommendation with those facts is the argument.

What if it was denied under the pharmacy benefit?

Check which benefit the claim ran under before appealing. A device denied under pharmacy is a different appeal path from one denied under the medical benefit, and filing on the wrong side loses time.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →